688298.SS SHH
Zhejiang Orient Gene Biotech Co., Ltd
1W: +2.0%
1M: +0.9%
3M: +1.1%
YTD: -22.0%
1Y: -32.0%
3Y: -49.3%
5Y: -81.0%
¥19.37 ($2.89)
+0.45 (+2.38%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$959M
+15.8% ▲
5Y CAGR: -21.7%
Gross Profit
$959M
+468.6% ▲
5Y CAGR: -18.0%
Operating Income
-$576M
+0.5% ▲
Net Income
-$564M
-6.5% ▼
EPS (Diluted)
$-2.93
-8.9% ▼
EBITDA
-$398M
-3.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $10.2B | $8.8B | $820M | $828M | $959M |
| YoY Growth | +211.4% | -13.8% | -90.6% | +0.9% | +15.8% |
| Cost of Revenue | $2.7B | $4.3B | $467M | $565M | $0 |
| Gross Profit | $7.5B | $4.5B | $353M | $60M | $959M |
| Gross Margin | 73.8% | 50.8% | 43.0% | 7.2% | 100.0% |
| R&D Expenses | $429M | $512M | $261M | $290M | $0 |
| SG&A Expenses | $1.1B | $601M | $290M | $203M | $0 |
| Operating Expenses | $1.6B | $1.3B | $737M | $842M | $1.5B |
| Operating Income | $5.8B | $3.7B | -$658M | -$763M | -$576M |
| Operating Margin | 56.8% | 42.0% | -80.3% | -92.2% | -60.0% |
| Interest Expense | $936K | $7M | $18M | $21M | $0 |
| Income Before Tax | $5.8B | $2.5B | -$404M | -$585M | -$577M |
| Tax Expense | $829M | $373M | $14M | -$16M | -$13M |
| Net Income | $4.9B | $2.1B | -$398M | -$529M | -$564M |
| Net Margin | 48.4% | 23.6% | -48.5% | -63.9% | -58.8% |
| EPS (Diluted) | $34.17 | $12.31 | $-1.97 | $-2.60 | $-2.93 |
| EBITDA | $5.8B | $2.6B | -$200M | -$360M | -$398M |
| Shares Outstanding | 144M | 168M | 202M | 197M | 192M |